Voyager System
Phase 3- Indications
- Glioblastoma, Diffuse Midline Glioma
Company intelligence / Profile preview
EMulate Therapeutics
Bellevue, Washington, United Statesemulatetx.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Phase 3
01
Overview
EMulate’s ulRFE® device has shown encouraging human data in glioblastoma and diffuse midline glioma patients, with feasibility studies completed in phase 1/2. Preclinical models have demonstrated efficacy in pain management and mental health disorders. Animal studies show positive results across more than 20 solid tumor types. The company is preparing for pivotal phase III trials.
- Therapeutic areas
- OncologyPsychiatryImmunologyNeurology
- Modalities
- DeviceNon-pharmacological therapy (ultra-low radio frequency energy device)
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 asset03
Partnerships
Hapbee Technologies — licensed consumer wellness-wearable technology based on ulRFE platform; EMulate is largest independent shareholder & receives royalties from net sales.
Beyond the preview
Go deeper on EMulate Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMulate Therapeutics.